To read the full story
Related Article
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- EU Panel Backs Astellas’ Hot Flash Drug
October 17, 2023
- Astellas’ Hot Flash Med Nets Positive PIIIb Results in Europe
June 29, 2023
- Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
- FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- EMA Accepts Astellas’ Hot Flash Drug for Review
October 3, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
- Astellas’ Vasomotor Symptom Med Missed Primary Goal in Asian PIII Study
March 16, 2022
BUSINESS
- BMS Oncology VP Goto to Lead Argenx Japan
April 25, 2025
- Gilead Files Trodelvy for HR+/HER2- Breast Cancer in Japan
April 25, 2025
- Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
- Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
- Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…